Exploring the role of monitoring anti-TNFα drug and antibody levels in the management of inflammatory bowel disease

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 2, 2011, Pages 145-151

  Lim, Allen W ^a   Panaccione, Remo ^a   Seow, Cynthia H ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Anti TNF ; Antibodies; Inflammatory bowel disease; Pharmacokinetics

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DRUG ANTIBODY; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

EID: 79953315171     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X10382816     Document Type: Review

References (27)

1. Afif W. Loftus E.V. Jr Faubion W.A. Kane S.V. Bruining D.H. Hanson K.A. et al (2010) Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol, in press.
2. Baert F. Noman M. Vermeire S. van Assche G. D’ Haens G. Carbonez A. et al (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601–608.
3. Bernstein C.N. Wajda A. Svenson L.W. MacKenzie A. Koehoorn M. Jackson M. et al (2006) The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 101: 1559–1568.
4. Colombel J.F. Sandborn W.J. Rutgeerts P. Enns R. Hanauer S.B. Panaccione R. et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52–65.
5. Farrell R.J. Alsahli M. Jeen Y.T. Falchuk K.R. Peppercorn M.A. Michetti P. (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124: 917–924.
6. Feagan B.G. McDonald J.W. Panaccione R. Enns R.A. Bernstein C.N. Ponich T.P. et al (2008) A randomized trial of Methotrexate in combination with infliximab for the treatment of Crohn's disease. Presented at Digestive Disease Week; May 17–22; 2008. San Diego, CA. Gastroenterology 135: 294–295.
7. Hanauer S.B. (1996) Inflammatory bowel disease. N Engl J Med 334: 841–848.
8. Hanauer S.B. Feagan B.G. Lichtenstein G.R. Mayer L.F. Schreiber S. Colombel J.F. et al (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541–1549.
9. Hanauer S.B. Sandborn W.J. Rutgeerts P. Fedorak R.N. Lukas M. MacIntosh D. et al (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323–333, quiz 591.
10. Hanauer S.B. Wagner C.L. Bala M. Mayer L. Travers S. Diamond R.H. et al (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2: 542–553.
11. Karmiris K. Paintaud G. Noman M. Magdelaine-Beuzelin C. Ferrante M. Degenne D. et al (2009) Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137: 1628–1640.
12. Knight D.M. Trinh H. Le J. Siegel S. Shealy D. McDonough M. et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30: 1443–1453.
13. Maser E.A. Villela R. Silverberg M.S. Greenberg G.R. (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4: 1248–1254.
14. Papadakis K.A. Targan S.R. (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119: 1148–1157.
15. Rutgeerts P. Sandborn W.J. Feagan B.G. Reinisch W. Olson A. Johanns J. et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353: 2462–2476.
16. Sandborn W.J. Colombel J.F. Enns R. Feagan B.G. Hanauer S.B. Lawrance I.C. et al (2005) Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353: 1912–1925.
17. Sandborn W.J. Feagan B.G. Stoinov S. Honiball P.J. Rutgeerts P. Mason D. et al (2007 a) Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357: 228–238.
18. Sandborn W.J. Hanauer S.B. Rutgeerts P. Fedorak R.N. Lukas M. MacIntosh D.G. et al (2007 b) Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 56: 1232–1239.
19. Sandborn W.J. Rutgeerts P. Enns R. Hanauer S.B. Colombel J.F. Panaccione R. et al (2007 c) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146: 829–838.
20. Sandborn W.J. Rutgeerts P. Reinishch W. Mantzaris G. Kornbluth A. Rachmilewetz D. (2008 b) SONIC: A randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Am J Gastroenterol 103: 1117–1117, Late-breaking abstract 1129.
21. Sandborn W.J. Rutgeerts P. Reinishch W. Mantzaris G. Kornbluth A. Rachmilewetz D. (2009) One year data from the SONIC study: a randomized, double-blind trial comparing infliximab and infiximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gastroenterology 136: A116–A116.
22. Sands B.E. Anderson F.H. Bernstein C.N. Chey W.Y. Feagan B.G. Fedorak R.N. et al (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350: 876–885.
23. Schreiber S. Khaliq-Kareemi M. Lawrance I.C. Thomsen O.O. Hanauer S.B. McColm J. et al (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239–250.
24. Seow C.H. Newman A. Irwin S.P. Steinhart A.H. Silverberg M.S. Greenberg G.R. (2010) Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59: 49–54.
25. St Clair E.W. Wagner C.L. Fasanmade A.A. Wang B. Schaible T. Kavanaugh A. et al (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46: 1451–1459.
26. van Assche G. van Ranst M. Sciot R. Dubois B. Vermeire S. Noman M. et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353: 362–368.
27. Vermeire S. Noman M. van Assche G. Baert F. D'Haens G. Rutgeerts P. (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56: 1226–1231.